Eric Low, Chief Executive of Myeloma UK, explains the evolving strategies for improving the drug development process for therapies for patients with multiple myeloma so that the right therapies are delivered to the right patients. One such strategy is the Myeloma UKs Clinical Trial Network, which comprises of experts, hospitals and research centres across the UK aimed at accelerating the testing of and access to new myeloma therapies.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.